Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition

References

• Pol J, Bloy N, Obrist F, Eggermont A, Galon J, Cremer I, Erbs P, Limacher JM, Preville X, Zitvogel L et al. Trial Watch:: Oncolytic viruses for cancer therapy. Oncoimmunology 2014; 3:e28694; PMID:25097804; http://dx.doi.org/10.4161/onci.28694
   PubMed Web of Science ®Google Scholar
• Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J clin Oncol 2015; 33:2780-8; PMID:26014293; http://dx.doi.org/10.1200/JCO.2014.58.3377
   PubMed Web of Science ®Google Scholar
• Lusky M, Erbs P, Foloppe J, Acres RB. Oncolytic vaccinia virus: a silver bullet? Exp Rev Vaccines 2010; 9:1353-6; PMID:21105770; http://dx.doi.org/10.1586/erv.10.137
   PubMed Web of Science ®Google Scholar
• Chan WM, McFadden G. Oncolytic poxviruses. Annu Rev Virol 2014; 1:119-41; PMID:25839047; http://dx.doi.org/10.1146/annurev-virology-031413-085442
   PubMed Web of Science ®Google Scholar
• Erbs P, Regulier E, Kintz J, Leroy P, Poitevin Y, Exinger F, Jund R, Mehtali M. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res 2000; 60:3813-22; PMID:10919655
   PubMed Web of Science ®Google Scholar
• Foloppe J, Kintz J, Futin N, Findeli A, Cordier P, Schlesinger Y, Hoffmann C, Tosch C, Balloul JM, Erbs P. Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus. Gene Ther 2008; 15:1361-71; PMID:18480846; http://dx.doi.org/10.1038/gt.2008.82
   PubMed Web of Science ®Google Scholar
• Parato KA, Breitbach CJ, Le Boeuf F, Wang J, Storbeck C, Ilkow C, Diallo JS, Falls T, Burns J, Garcia V et al. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther 2012; 20:749-58; PMID:22186794; http://dx.doi.org/10.1038/mt.2011.276
   PubMed Web of Science ®Google Scholar
• Breitbach CJ, Arulanandam R, De Silva N, Thorne SH, Patt R, Daneshmand M, Moon A, Ilkow C, Burke J, Hwang TH et al. Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans. Cancer Res 2013; 73:1265-75; PMID:23393196; http://dx.doi.org/10.1158/0008-5472.CAN-12-2687
   PubMed Web of Science ®Google Scholar
• Kirn DH, Thorne SH. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer 2009; 9:64-71; PMID:19104515; http://dx.doi.org/10.1038/nrc2545
   PubMed Web of Science ®Google Scholar
• Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, Vitale I, Goubar A, Baracco EE, Remedios C et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med 2014; 20:1301-9; PMID:25344738; http://dx.doi.org/10.1038/nm.3708
   PubMed Web of Science ®Google Scholar
• Guo ZS, Liu Z, Bartlett DL. Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity. Front Oncol 2014; 4:74; PMID:24782985; http://dx.doi.org/10.3389/fonc.2014.00074
   PubMedGoogle Scholar
• John LB, Howland LJ, Flynn JK, West AC, Devaud C, Duong CP, Stewart TJ, Westwood JA, Guo ZS, Bartlett DL et al. Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer. Cancer Res 2012; 72:1651-60; PMID:22315352; http://dx.doi.org/10.1158/0008-5472.CAN-11-2788
   PubMed Web of Science ®Google Scholar
• Rojas J, Sampath P, Hou W, Thorne SH. Defining effective combinations of immune checkpoint blockade and oncolytic virotherapy. Clin Cancer Res 2015. 24:5543-51; PMID:26187615; http://dx.doi.org/10.1158/1078-0432.CCR-14-2009
   Web of Science ®Google Scholar
• Khan H, Gucalp R, Shapira I. Evolving concepts: immunity in oncology from targets to treatments. J Oncol 2015; 2015:847383; PMID:26060497; http://dx.doi.org/10.1155/2015/847383
   PubMed Web of Science ®Google Scholar
• Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015; 27:450-61; PMID:25858804; http://dx.doi.org/10.1016/j.ccell.2015.03.001
   PubMed Web of Science ®Google Scholar
• Kaplan B, Livneh A, Sela BA. Immunoglobulin free light chain dimers in human diseases. Scient World J 2011; 11:726-35; PMID:21442150; http://dx.doi.org/10.1100/tsw.2011.65
   Web of Science ®Google Scholar
• Li C, Rossomando A, Wu SL, Karger BL. Comparability analysis of anti-CD20 commercial (rituximab) and RNAi-mediated fucosylated antibodies by two LC-MS approaches. mAbs 2013; 5:565-75; PMID:23751726; http://dx.doi.org/10.4161/mabs.24814
   PubMed Web of Science ®Google Scholar
• Ansari MJ, Salama AD, Chitnis T, Smith RN, Yagita H, Akiba H, Yamazaki T, Azuma M, Iwai H, Khoury SJ et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 2003; 198:63-9; PMID:12847137; http://dx.doi.org/10.1084/jem.20022125
   PubMed Web of Science ®Google Scholar
• Paul S, Bizouarne N, Dott K, Ruet L, Dufour P, Acres RB, Kieny MP. Redirected cellular cytotoxicity by infection of effector cells with a recombinant vaccinia virus encoding a tumor-specific monoclonal antibody. Cancer Gene Ther 2000; 7:615-23; PMID:10811480; http://dx.doi.org/10.1038/sj.cgt.7700161
   PubMed Web of Science ®Google Scholar
• Paul S, Regulier E, Rooke R, Stoeckel F, Geist M, Homann H, Balloul JM, Villeval D, Poitevin Y, Kieny MP et al. Tumor gene therapy by MVA-mediated expression of T-cell-stimulating antibodies. Cancer Gene Ther 2002; 9:470-7; PMID:11961670; http://dx.doi.org/10.1038/sj.cgt.7700461
   PubMed Web of Science ®Google Scholar
• Frentzen A, Yu YA, Chen N, Zhang Q, Weibel S, Raab V, Szalay AA. Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy. Proc Natl Acad Sci U S A 2009; 106:12915-20; PMID:19617539; http://dx.doi.org/10.1073/pnas.0900660106
   PubMed Web of Science ®Google Scholar
• Engeland CE, Grossardt C, Veinalde R, Bossow S, Lutz D, Kaufmann JK, Shevchenko I, Umansky V, Nettelbeck DM, Weichert W et al. CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy. Mol Thera 2014; 22:1949-59; PMID:25156126; http://dx.doi.org/10.1038/mt.2014.160
   PubMed Web of Science ®Google Scholar
• Dias JD, Hemminki O, Diaconu I, Hirvinen M, Bonetti A, Guse K, Escutenaire S, Kanerva A, Pesonen S, Loskog A et al. Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4. Gene Ther 2012; 19:988-98; PMID:22071969; http://dx.doi.org/10.1038/gt.2011.176
   PubMed Web of Science ®Google Scholar
• Marabelle A, Kohrt H, Caux C, Levy R. Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res 2014; 20:1747-56; PMID:24691639; http://dx.doi.org/10.1158/1078-0432.CCR-13-2116
   PubMed Web of Science ®Google Scholar
• Marabelle A, Kohrt H, Levy R. Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicity. Clin Cancer Res 2013; 19:5261-3; PMID:23965900; http://dx.doi.org/10.1158/1078-0432.CCR-13-1923
   PubMed Web of Science ®Google Scholar
• Palazon A, Martinez-Forero I, Teijeira A, Morales-Kastresana A, Alfaro C, Sanmamed MF, Perez-Gracia JL, Penuelas I, Hervas-Stubbs S, Rouzaut A et al. The HIF-1alpha hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy. Cancer Dis 2012; 2:608-23; PMID:22719018; http://dx.doi.org/10.1158/2159-8290.CD-11-0314
   Web of Science ®Google Scholar
• Rosel JL, Earl PL, Weir JP, Moss B. Conserved TAAATG sequence at the transcriptional and translational initiation sites of vaccinia virus late genes deduced by structural and functional analysis of the HindIII H genome fragment. J Virol 1986; 60:436-49; PMID:3021979
   PubMed Web of Science ®Google Scholar
• Cochran MA, Puckett C, Moss B. In vitro mutagenesis of the promoter region for a vaccinia virus gene: evidence for tandem early and late regulatory signals. J Virol 1985; 54:30-7; PMID:3973982
   PubMed Web of Science ®Google Scholar